Insights
Search Results
Client Highlights
6.01.26
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to $32.5 Million Series A Financing
On June 1, 2026, Oak Hill Bio, a clinical-stage rare disease therapeutics company, announced the closing of a $32.5 million Series A financing. The round was co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors, with participation from KCap Biotechnology Fund. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.
Client Highlights
10.01.25
Firm Advises Predicta Biosciences on IP Matters Related to Oversubscribed $23.4 Million Series A
On October 1, 2025, Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, announced it has raised an oversubscribed $23.4 million Series A financing led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute, and Myeloma Solutions Fund. Wilson Sonsini Goodrich & Rosati advised Predicta on IP matters related to the transaction.
Client Highlights
4.15.25
Wilson Sonsini Advises Oak Hill Bio on Patent Matters Related to Exclusive License Agreement with Roche
On April 15, 2025, Oak Hill Bio, a biotechnology company focused on acquiring and developing life-changing rare disease therapeutics, entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). Rugonersen is an ASO designed as a potential best-in-class treatment for individuals with Angelman syndrome, a rare, genetic neurodevelopmental condition for which there is no approved disease-modifying treatment. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.